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Abstract 
Although tyrosine kinase inhibitors is effective for dramatically reducing CML cells, it might be 
difficult to eradicate completely the CML stem cells. We aimed to clarify the safety and effects 
of WT1 peptide vaccination in combination with imatinib therapy for a CML patient.  A 51 
year-old male with CML in CP, who showed a resistance against imatinib therapy for 2.5 years, 
began to be treated with 9mer modified-type WT1 peptides in combination with standard 
dose of imatinib. Although every 2-week-administration of WT1 peptides for 22 weeks did 
not show definite effects on the quantification of bcr-abl transcripts, by changing the admin-
istration from every 2 weeks to 4 weeks bcr-abl transcripts decreased remarkably.  After 11 
months of every 4-week-administration of the peptides and 12 months post cessation of the 
peptides bcr-abl transcripts achieved to the level below detection by RQ/RT-PCR (complete 
molecular response). WT1/MHC tetramer
+CD8
+ CTLs, which appeared after the second 
administration of WT1 peptides and remained more than 15 in number among 10
6 CD8
+ T 
cells throughout the administration of WT1 peptides, are still present in the blood on 14th 
month post cessation of the peptides.  An in vitro study as to the cytotoxicity of lymphocytes 
induced by mixed lymphocyte peptide culture demonstrated that cultured lymphocytes 
possessed cytotoxicity against WT1 expressing leukemia cells and the cytotoxicity was 
WT1-specific and MHC class I restricted. The present study showed that WT1 peptide 
vaccination in combination with TKI is feasible and effective in the therapy for imati-
nib-resistant CML. 
Key words: WT1 peptide vaccination, CML, imatinib, bcr-abl transcripts, WT1 tetramer, cytotoxic-
ity 
INTRODUCTION 
While tyrosine kinase inhibitors (TKIs) such as 
imatinib are currently regarded as the first line ther-
apy for chronic myelogenous leukemia (CML), it 
seems that CML stem cells display intrinsic resistance Int. J. Med. Sci. 2010, 7 
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against most TKIs [1].  Therefore, extermination of 
CML stem cells could be critically needed for CML 
patients to be fully liberated from the TKI therapy.  
On the other hand, anti-tumor cytotoxic T lympho-
cytes (CTLs) are presumed to kill the relevant anti-
gen-expressing tumor cells including resting cells 
such as tumor stem cells and spare normal hemato-
poietic progenitor cells [2].   
Although the Wilms’ tumor 1 (WT1) gene was 
first isolated as a tumor suppressor gene associated 
with the Wilms’ tumor, the WT1 gene has been shown 
to be highly expressed in hematopoietic malignancies 
including acute and chronic myelogenous leukemia, 
acute lymphocytic leukemia and myelodysplastic 
syndrome, and a majority of solid tumors including 
glioblastoma, lung cancer, breast cancer, colorectal 
cancer, thyroid cancer, renal cancer, bone/soft tissue 
sarcoma and head/neck squamous cell carcinoma [3].  
WT1-specific CTLs with HLA-A*0201 or A*2402 could 
be generated by stimulating peripheral blood mono-
nuclear cells (PB-MNCs) with WT1 peptide-pulsed 
antigen presenting cells (APCs) in several laboratories 
[4-6]. WT1 peptides have already been used in clinical 
trials for specific immunotherapy of HLA-A24+ pa-
tients with brain tumor, breast cancer, colorectal can-
cer, thyroid cancer, leiomyosarcoma, or hematological 
malignancies including acute myeloid leukemia 
(AML), myeloma and myelodysplastic syndrome 
(MDS) [7].   
In order to eradicate minimum residual CML 
cells which survived long-term imatinib therapy, we 
started WT1 peptide vaccination therapy in combina-
tion with imatinib in a CML patient who could not 
acquire a major molecular response through the ad-
ministration with a single agent of imatinib.  In addi-
tion, we tried to monitor the kinetics of WT1-specific 
CTLs as well as low frequency immunocompetent 
cells such as plasmacytoid DCs (pDCs), myeloid 
dendritic cell-1s (mDC1s), γδT cells and regulatory T 
(Treg) cells in peripheral blood (PB) during WT1 pep-
tide vaccination.    
MATERIALS AND METHODS 
Administration of WT1 peptide 
Modified-type WT1 peptide (HLA-A*2402- 
restricted, 9-mer peptide; CYTWNQMNL) was syn-
thesized in GMP grade by NeoMPS (San Diego, CA, 
USA).  WT1 peptide was dissolved with DMSO (Sig-
ma-Aldrich, St. Louis, MO, USA) and then diluted 
with 5% glucose.  A water-in-oil emulsion was pre-
pared by mixing WT1 peptide as the aqueous phase 
and the adjuvant Montanide ISA-51 VG (Seppic, Paris, 
France) as the oil phase. The emulsion (WT1 peptide 
concentration: 3.33 mg/ml) was administered subcu-
taneously at the dose of 1 mg/body at 2 different sites 
such as the upper arm and thigh.  The administration 
of WT1 peptides was performed after informed con-
sent was obtained according to the protocol approved 
by the IRB of Niigata University School of Medicine. 
Mixed lymphocyte peptide culture (MLPC) 
MLPC was initiated by culturing 1-3 x105 
PB-MNCs in 100 μl of 5% autologous se-
rum-containing RPMI1640 with 10 μg modified-type 
WT1 peptides in 96 well plates in a modification of the 
method described by Karanikas et al [8]. Three days 
later RPMI1640 with 50 IU/ml IL-2 (Shionogi, Osaka, 
Japan) was added and a half of culture medium was 
changed every 3 days thereafter.  After culturing for 
two weeks, cultured cells in each well were indivi-
dually analyzed for various surface phenotypes, WT1 
peptide/HLA-A*2402 tetramer and WT1-specific cy-
totoxicity by using flow cytometry.   
Frequency of WT1 peptide/HLA-A*2402 tetra-
mer
+ cells  
Modified-type WT1 peptide/HLA-A*2402 te-
tramer and HIV-1 env peptide 
(HLA-A*2402-restricted, 9-mer peptide; sequence: 
RYLRDQQLL)/HLA-A*2402 tetramer were kindly 
provided by Dr. K Kuzushima (Aichi Cancer Center 
Research Institute).  Wild-type WT1 peptide 
(HLA-A*2402-restricted, modified 9-mer peptide; se-
quence: CMTWNQMNL)/HLA-A*2402 tetramer was 
purchased from MBL (Nagoya, Japan).  For the te-
tramer assay, MLPC cells were double-stained with 
the FITC-CD8 antibody (BD Biosciences, San Jose, CA, 
USA) and PE-tetramer.  HIV-1 env pep-
tide/HLA-A*2402 tetramer was used as the negative 
control.  Stained cells were analyzed with FACScan 
flow cytometry (BD Biosciences) and the data were 
analyzed by CellQest software (BD Biosciences). Fre-
quency of WT1 peptide/HLA-A*2402 tetramer+ cells 
in PB-CD8+ cells was calculated by the following 
formula. Number of wells contain ing a lump of te-
tramer+CD8+ cells / (Number of PB-MNCs seeded in 
a well of MLPC) x (total number of wells for MLPC) x 
(ratio of number of PB-CD8+ cells in PB-MNCs).  As to 
the frequencies of modified-type and wild-type WT1 
peptide/HLA-A*2402 tetramer+CD8+ T cells, al-
though the binding stability of wild-type WT1 pep-
tide/HLA-A*2402 tetramer  was lower than that of 
modified-type WT1 peptide/HLA-A*2402 tetramer, 
the frequencies of WT1 peptide/HLA-A*2402 tetra-
mer+CD8+ T cells were almost the same between 
wild-type and modified-type tetramers.  These data 
suggested that the frequency of wild-type WT1 pep-Int. J. Med. Sci. 2010, 7 
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tide/ HLA-A*2402 tetramer+CD8+ T cells could be 
replaced by that of modified-type WT1 peptide/ 
HLA-A*2402 tetramer+CD8+ T cells.  Therefore, in the 
present study, the frequency of WT1/MHC tetra-
mer+CD8+ T cells was calculated from flow cytometry 
analysis using modified-type WT1 pep-
tide/HLA-A*2402 tetramer. 
Identification of pDCs, mDC1s, γδT cells, Treg 
cells 
For identification of pDCs, mDC1s, γδT cells and 
T r e g  c e l l s ,  P B - m o n o n u c l e a r  c e l l s  ( M N C s )  w e r e  p r e -
pared from a WT1 peptide-treated patient and stained 
w i t h  F I T C ,  P E  o r  A P C - l a beled various monoclonal 
antibodies. pDCs were identified as CD303+ (BDCA2; 
Miltenyi Biotec, Bergisch Gladbach, Germany) cells.  
mDC1s were identified as lineage (CD3, CD14, CD19 
and CD56)- / CD1c+ (BDCA1; Miltenyi Biotec) cells. 
γδT cells were identified as CD3+/γδTCR+ cells. For 
identification of Treg cells, PB-MNCs were stained 
with surface molecules such as CD4 and CD25 (BD 
Biosciences). Then the cells were treated with freshly 
prepared Fixation/Permeabilization working solution 
(eBioscience, San Diego, CA) for 60 minutes and 
stained with PE-conjugated anti-human Foxp3 anti-
body (eBioscience) or isotype control. Treg cells were 
identified as CD4+/Foxp3+ cells. Cell fluorescence was 
analyzed with FACSAria flow cytometry (BD Bios-
ciences) and 10,000 events were collected, the data of 
which was analyzed by FACSDiva software (BD Bi-
osciences). 
Cytotoxicity assay  
To estimate anti-WT1 cytotoxicity of MLPC cells, 
a 5,6-carboxy-fluorescein succinimidyl ester (CFSE; 
Molecular Probes, Eugene, OR)-based cytotoxicity 
assay was performed.  Autologous EB-virus trans-
formed B-lymphoblastoid cell line (B-LCL) cells 
pulsed with WT1 peptides were labeled with 10 μM 
CFSE, and were used as target cells for the cytotoxic-
ity assay.  Labeled target cells were co-cultured in 
tubes with effector cells for 4 hours at 37ºC in a fully 
humidified 5% CO2 atmosphere.  Co-cultured cells 
(consisting of effector cells and target cells) were 
stained with 7AAD to identify dead cells, and a fixed 
amount (10,000 beads/tube) of FITC-labeled Cali-
BRITE beads (BD Biosciences) were added for quan-
titative analysis of the cell population just prior to 
flow cytometry analysis. Viable target cells 
(CFSE+/7AAD-) and CaliBRITE beads were gated in 
FSC/SSC and FL-1/FSC dot plots respectively in tar-
get cells, which had been cultured without effector 
cells. For each sample tube containing target cells with 
effector cells at various effector-to-target ratios, 5,000 
CaliBRITE beads were acquired, which made it poss-
ible to calculate the absolute numbers of viable target 
cells. Percent cytotoxicity of the assay was calculated 
by the following formula. : % cytotoxicity = [(absolute 
number of viable target cells in the tube containing 
target cells only –absolute number of viable target 
cells in the sample tube containing target cells and 
effector cells)/absolute number of viable target cells 
in the tube containing target cells only] x 100. 
Unlabeled target cell-mediated blocking of cy-
totoxicity by CTLs  
CFSE-labeled target cells were mixed with the 
same unlabeled target cells at the ratio of 1:5-20 
(CSFE-labeled target cells : unlabeled target cells)  and 
co-cultured with effector cells for the cytotoxicity as-
say. 
Anti-MHC class I monoclonal antibody-mediated 
blocking of cytotoxicity by CTLs  
Target cells were incubated with anti-MHC class 
I monoclonal antibody (clone W6/32, mouse IgG2a; 
Serotec, Oxford, UK), anti-MHC class II monoclonal 
antibody (clone Tu39, mouse IgG2a; BD Pharmingen, 
San Diego, CA) or isotype control (clone MPC-11, 
mouse IgG2a; BD Pharmingen) at 10 μg/ml for 30 min 
and then co-cultured with effector cells for the cyto-
toxicity assay. 
RESULTS 
1. Clinical efficacy of WT1 peptide vaccination 
A 51 year-old male with CML in chronic phase 
had been treated with 400 mg imatinib for two and a 
half years. Although bcr-abl transcripts decreased 
transiently to less than 1,000 copies in 1 μg RNA ex-
tracted from PB cells (3-log reduction = 280 copies in 1 
μg cellular RNA; median in our laboratory, n=120) 
during the imatinib treatment, the transcripts gradu-
ally increased to more than 4,000 copies sponta-
neously thereafter.  Imatinib was increased to a dose 
of 600 mg and continued for 4 months, which caused 
adverse effects such as worsening of anemia and limb 
pain with increased CK.  Therefore the dose of imati-
nib was decreased to 400 mg.  Thereafter bcr-abl 
transcripts decreased transiently to 500 copies during 
the imatinib treatment, which was speculated to be 
the late effects of imatinib therapy at the dose of 600 
mg a day.  However, bcr-abl transcripts gradually 
increased to more than 1,000 copies thereafter.  Since 
the patient was HLA-A*2402+ and informed consent 
was obtained, modified-type WT1 peptides, which 
had been identified to possess an anti-tumor immu-
nogenicity [7], were administered subcutaneously at 
the dose of 1 mg every 2 weeks in combination with Int. J. Med. Sc
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treatment or who experienced relapse of the disease. 
They showed that 1 patient had cytogenetic CR and 
three patients refractory to allogeneic transplantation, 
interferon and imatinib had stable disease with some 
hematological improvement [22]. 
We administered WT1 peptides to one patient 
who showed an increase of bcr-abl transcripts after 
getting into complete cytogenetic response but not 
3-log reduction throughout the previous treatment 
with imatinib for two and a half years. Modified-type 
WT1 peptides were used instead of wild-type WT1 
peptides because modified-type WT1 peptides had 
been demonstrated to possess a much higher binding 
capacity to the complementary determining region 
(CDR) of HLA-A*2402 and a more potent capacity to 
generate WT1 specific CTLs in vitro than wild-type 
WT1 peptides.  By administration of WT1 peptides 
every two weeks in combination with the same 
amount of imatinib, the tendency of increase of 
bcr-abl transcripts was abrogated and the patient 
showed a slight decrease of bcr-abl transcripts after 
the 4th administration of WT1 peptides. However, by 
repeated every two-week administration of WT1 
peptides, bcr-abl transcripts tended to increase after 
the 8th administration of WT1 peptides.  Referring to 
a report that the tetramer binding capacity and spe-
cific cytotoxicity of the CTL line decreases remarkably 
by the stimulation of relevant peptide-pulsed cells [9], 
we performed an in vitro study regarding the effects 
of WT1 peptide stimulation on the kinetics of 
WT1/MHC tetramer+CD8+ cells in cells generated by 
MLPC for 2 weeks.  Our study demonstrated that 
stimulation with WT1 peptides promptly decreased 
the absolute number of WT1/MHC tetramer+CD8+ 
cells and the decrease was maintained for two to three 
weeks.  On the other hand, in MLPC cells without the 
addition of WT1 peptides, the absolute number of 
WT1/MHC tetramer+CD8+ cells increased and main-
tained a high level during the entire period of the 
culturing (data not shown).  Considering that the 
same phenomenon could occur in vivo, we changed 
WT1 peptide administration from every two weeks to 
every four weeks from the 12th administration. Al-
though bcr-abl transcripts increased considerably af-
ter the 12th administration of WT1 peptides, there 
was a gradual decrease of the transcripts thereafter to 
the level of complete molecular response after 11 
months from the cessation of WT1 peptide admi-
nistdration for 17 months (total administration: 22 
times, every four-week administration: 11 times). 
As to the frequency of WT1/MHC tetra-
mer+CD8+ cells in PB of the patients treated with WT1 
peptides, WT1 tetramer+CD8+ cells, which were not 
detected before the administration of WT1 peptides, 
appeared after the second administration of WT1 
peptides.  Even in the period in which bcr-abl tran-
scripts kept increasing from 16 to 29 weeks of WT1 
peptide treatment, the frequency of WT1/MHC te-
tramer+CD8+ cells maintained a high level. This may 
be due to blood drawn two or four weeks after the 
administration of WT1 peptides (immediately before 
the next administration). This is the time in which 
WT1/MHC tetramer+CD8+ cells had recovered from 
the nadir phase caused by WT1 peptides administered 
two or four weeks previously. It is speculated that 
during this period (at least for two weeks after the 
administration of WT1 peptides), the number of 
WT1/MHC tetramer+CD8+ cells had decreased and 
the cytotoxicity of anti-WT1 CTLs had been low, 
which could be associated with an elevation of bcr-abl 
transcripts. 
Cells induced by MLPC for two weeks showed 
cytotoxicity against the leukemia cell line expressing 
both HLA-A*2402 and WT1 antigen as well as WT1 
peptide-pulsed B-LCL.  The cytotoxicity of MLPC 
cells was suppressed by adding non-labeled target 
cells in the cytotoxicity assay using CFSE-labeled and 
WT1 peptide pulsed autologous B-LCL as target cells. 
Besides, the cytotoxicity of MLPC cells was sup-
pressed by treating target cells with anti-MHC class I 
monoclonal antibodies but not with anti-MHC class II 
monoclonal antibodies in the CFSE-labeled target cy-
totoxicity assay. These findings revealed that MLPC 
cells possess cytotoxicity specific to the WT1 antigen 
and restricted to MHC class I. 
By repeated administration of WT1 peptides, 
Treg cells increased after 20 weeks from the initiation 
of WT1 vaccination, which was a simultaneous event 
as increase of bcr-abl transcripts of PB cells. The asso-
ciation of an increase of Treg cells and elevation of 
bcr-abl transcripts is not clear but it can be easily 
speculated that Treg cells might play a negative role 
in anti-tumor immunotherapy as in this case. These 
data suggested the possible usefulness of treatment 
for suppressing the function of regulatory T cells in 
combination with anti-tumor immunotherapy in-
cluding tumor antigen peptide vaccination.  
The present study showed that WT1 peptide 
vaccination for imatinib-pretreated CML patients is 
feasible and presumed to be effective for reducing 
leukemia cells, which was supported by the appear-
ance of WT1/MHC tetramer+CD8+ T cells with an-
ti-leukemic cytotoxicity in PB of a CML patient treated 
with WT1 peptide vaccination.   
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